<SEC-DOCUMENT>0001213900-22-061528.txt : 20221004
<SEC-HEADER>0001213900-22-061528.hdr.sgml : 20221004
<ACCEPTANCE-DATETIME>20221004060136
ACCESSION NUMBER:		0001213900-22-061528
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		6
CONFORMED PERIOD OF REPORT:	20221004
FILED AS OF DATE:		20221004
DATE AS OF CHANGE:		20221004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuron Ltd
		CENTRAL INDEX KEY:			0001660046
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38104
		FILM NUMBER:		221289651

	BUSINESS ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
		BUSINESS PHONE:		61 03 9824 5254

	MAIL ADDRESS:	
		STREET 1:		62 LYGON STREET
		STREET 2:		LEVEL 3
		CITY:			CARLTON, VICTORIA
		STATE:			C3
		ZIP:			3053
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea166698-6k_immuron.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE
COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form 6-K</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the Month of October 2022</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File Number: 001-38104</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>IMMURON LIMITED</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name of Registrant)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Level 3, 62 Lygon
Street, Carlton South, Victoria, 3053, Australia</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive office)</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
Form 40-F <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether by furnishing the information contained
in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If &ldquo;Yes&rdquo; is marked, indicate below the file number assigned
to the registrant in connection with Rule 12g3-2(b): 82-</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>IMMURON LIMITED</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXPLANATORY NOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Immuron Limited (the &ldquo;Company&rdquo;) published one announcement
(the &ldquo;Public Notices&rdquo;) to the Australian Securities Exchange on October 4, 2022 titled:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">-</TD><TD STYLE="text-align: justify">&ldquo;Immuron Executes Travelan Clinical Trial Agreement Pharmaron&rdquo;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A copy of the Public Notice is attached as an exhibit to this report
on Form 6-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This report on Form 6-K (including the exhibit
hereto) shall not be deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange
Act&rdquo;) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 0; border-bottom: Black 1.5pt solid; text-align: center; width: 9%; vertical-align: bottom"><B>Exhibit</B><BR>
<FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="padding-bottom: 0; text-align: center; width: 1%; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="padding-bottom: 0; border-bottom: Black 1.5pt solid; text-align: center; width: 90%; vertical-align: bottom"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><A HREF="ea166698ex99-1_immuron.htm">IMC - Immuron Executes Travelan Clinical Trial Agreement Pharmaron</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.45in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt"><B>IMMURON LIMITED</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><IMG SRC="image_001.jpg" ALT=""></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date: October 4, 2022</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">/s/ Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Phillip Hains</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Company Secretary</FONT></TD></TR>
  </TABLE>
<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea166698ex99-1_immuron.htm
<DESCRIPTION>IMC - IMMURON EXECUTES TRAVELAN CLINICAL TRIAL AGREEMENT PHARMARON
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: right"><B>Exhibit 99.1</B><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Immuron
Executes Travelan Clinical Trial Agreement with US-based Pharmaron </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Highlights:</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
                                            Trial Master Service Agreement with US-based Pharmaron Executed</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investigational
                                            New Drug (IND) application to be submitted to the U.S. Food and Drug administration (FDA)</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Plans
                                            in place to initiate a Controlled Human Infection Model (CHIM) clinical trial in 60 healthy
                                            volunteers in the USA</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
                                            Trial to examine a dosing regimen for Travelan more suited for use by the US military</B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Infectious
                                            diarrhea is the most common illness reported by travelers </B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Melbourne,
Australia, October 04, 2022: Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical
company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is
pleased to announce that it has executed a Master Service Agreement with US-based Pharmaron CPC, Inc. a Maryland Corporation located
in Baltimore USA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase II clinical trial will evaluate the efficacy of a single dose regimen of Travelan&reg; in a controlled human infection model (CHIM)
using the enterotoxigenic <I>Escherichia coli</I> (ETEC) strain H10407. Previous US military field studies have shown that for military
personnel deployed in austere environments compliance is low with products dosed more than once per day. The proposed Travelan dosing
regime is potentially more amenable for use in military populations. The new planned clinical study will enrol up to 60 volunteers each
will be randomly assigned to receive either a once-daily dose of 1200 mg of Travelan&reg; or placebo. This study will occur across two
cohorts (n=15 Travelan&reg; subjects and n=15 placebo subjects per cohort), as the inpatient unit can accommodate up to 30 study participants
at a time. The proposed clinical development program is being funded in part by AU$6.2 (US$4.5) million award (ASX announcement January
12, 2022) from the US Department of Defense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
is currently on track to submit the Investigational New Drug (IND) application to the US Food and Drug Administration by end of 2022
and will be the sponsor of the clinical study which is planned to begin in 1H 2023 subject to FDA approval with headline results from
the clinical trial expected in 2H 2023.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Infectious
diarrhea is the most common illness reported by travelers visiting developing countries and among US troops deployed overseas. The morbidity
and associated discomfort stemming from diarrhea decreases daily performance, affects judgment, decreases morale and declines operational
readiness. The first line of treatment for infectious diarrhea is the prescription of antibiotics. Unfortunately, in the last decade,
several enteric pathogens have an increasing resistance to commonly prescribed antibiotics. In addition, travelers&rsquo; diarrhea is now recognized
by the medical community to result in post-infectious sequelae, including post-infectious Irritable Bowel Syndrome and several post-infectious
autoimmune diseases. A preventative treatment that protects against enteric diseases, is a high priority objective for the US Military.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release has been authorised by the directors of Immuron Limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">-
- - END - - -</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><IMG SRC="ex99-1_003.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMPANY CONTACT:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Steven Lydeamore</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ph: +61 (0)3 9824 5254</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">info@immuron.com</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelan&reg;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelan&reg;
is an orally administered passive immunotherapy that prophylactically reduces the likelihood of contracting travelers&rsquo; diarrhea,
<FONT STYLE="background-color: white">a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce</FONT>.
Travelan&reg; is a highly purified tabletized preparation of hyper immune bovine antibodies and other factors, which when taken with
meals bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers&rsquo; diarrhea. In Australia,
Travelan&reg; is a listed medicine on the Australian Register for Therapeutic Goods (AUST L 106709) and is indicated to reduce the risk
of Travelers&rsquo; Diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. In Canada, Travelan&reg; is
a licensed natural health product (NPN 80046016) and is indicated to reduce the risk of Travelers&rsquo; Diarrhea. In the U.S., Travelan&reg;
is sold as a dietary supplement for digestive tract protection.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Travelers&rsquo; diarrhea</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Travelers&rsquo;
diarrhea is a gastrointestinal infection with symptoms that include loose, watery (and occasionally bloody) stools, abdominal cramping,
bloating, and fever, Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic <I>Escherichia coli</I> (ETEC) playing
a dominant causative role. Campylobacter spp. are also responsible for a significant proportion of cases. The more serious infections
with Salmonella spp. the bacillary dysentery organisms belonging to Shigella spp. and Vibrio spp. (the causative agent of cholera) are
often confused with travelers&rsquo; diarrhea as they may be contracted while travelling and initial symptoms are often indistinguishable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Immuron</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Immuron
Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered
targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information visit: <U STYLE="text-decoration: none">http://www.immuron.com</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORWARD-LOOKING
STATEMENTS:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release may contain &ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements
relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking
statements are based on management&rsquo;s current expectations and are subject to risks and uncertainties that could negatively affect
our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from
those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing
and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the
timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial
additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our
SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking
statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which
any such statement is based, except as required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="ex99-1_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !$ #H# 2(  A$! Q$!_\0
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M+Y; 8(^0QA$V?=V*HVC H F@LXK<Q^6,"*/RHEW%@D?9%#9P!_>_UC?\M'?
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L2K%E*[@0&5N58#<IZ$9-%% $L*)'$D<:A$10J*.BJ. !G)P!QR:DHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !$ 0P# 2(  A$! Q$!_\0
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MW&K_ !5OY;IDTJ"**W!PKRKN=O?T%=QH_B1!X)AUS69XHE",TLF,#AB!@>O
MXIGAKP3INA649EMHKB]*CS)I%#8/HN>@KS7XL:C>:_XOL/!^F_<C*[HUX#2M
MSS[!2#^)I/V55JG35DNIKAZ=6_-4EOT(M=^,VMZK?&T\,61AC)(1C'YLS^X'
M0?3FJT>L_%VU47;Q:A)$/F*O:H0?P S7JWACPGH_@71BR",2JFZXO)!\S>O/
M8>@KF=6^+)2X,>E62/&I_P!;.3\WT4=/SJJ=IOEI037=FU6O3I?$.\%_%A=8
MOET?7[=;'4B=B-@JCMZ$'E37I^*\RU#0['XG^$SJ26B6>L1%A%,AYWKS@GNI
MSWZ5N^#_ !)/?^!8+^]C=[JU+07:X^;=&<,<>N,$CZUSU:<=XJSV:*4XRCSK
M8[#C K/UC6+'0[![R^EV1KP .2Q] .YJW!/%<V\<\#K)%(H9&4\$'O7BOQ)U
M>74O$[V:L3!:_(B?[7\1_/C\*,/1]K/E>W4PQ%;V4.9;E[4_BOJ<\S#3K>&V
MA[%QO<_TJK:?%+7X)0;@6]Q'GE6CVG\Q7<^$?!-AH^GQ3W=O'-?R*&=I%W>7
MG^$ ]/K6MK7A72=;M&BN;6-'(^2:-0KH?4'^E=+K8:+Y>33N<ZHXF2YN?7L1
M^&/%MCXFMRT.8[B/_60MU'N/45T-?/UA)<^#_&:I(V#;S^7)C@.AZ_@0<U[\
M#N4,O((S7/BJ*I-..S-\-5=1-2W1XO\ %7_D;T_Z]4_FU>K^&O\ D6-+_P"O
M6/\ ]!%>4?%7_D;T_P"O5/YM7J_AO_D6=+_Z]8__ $$5MB/]WIF.'_WBH>*:
M_P#\E!N_^O\ /_H=>_=Z\"U[_DH=U_V$/_9Z]][T8WX8>G^08/XI^O\ F<O\
M0O\ D2K[ZI_Z$*XSX0_\A74O^N"_^A5V?Q"_Y$F^_P" ?^A"N,^$/_(4U+_K
M@O\ Z%54O]TG_7857_>H?UW/7#7B_P 5A_Q5$!_Z=U_F:]H->,?%;_D9X?\
MKW7^9K/ ?QODR\=_"^:/3O"ISX6TO_KW3^5>-^)SGXA7G_7V/YBO8_"G_(JZ
M7_U[I_*O'/$PQ\0;S_K\'\Q6N$_C3^?YF>*_A0^7Y'O:?='TKG?':AO!>I@]
MH@?_ !X5T2?='TKG_''_ ")NI_\ 7'^HKAI?Q(^J.RM_#EZ,X3X1#_B<7Y_Z
M8#_T*O7.]>1_"+_D+ZA_UP7_ -"KUSO6^._C/Y&&"_@KYGCGQ9'_ !4ML?\
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M#B? ?_'YXA_["#?UKM#TKBO 9 O/$.2/^/\ ;^M=H2"."*VQ/\1_+\D88?\
MAKY_FS@/!QQX4U[WFG_]!K+^'CMI%WIX=C]GUB!RN3TEC=AC\OYUJ>#A_P 4
MIKQ])I__ $&J5G9R2_"O3+^WS]ITZ1KF/'H)&W#\OY5U-J\XOJTOP_S.5;0D
MNB;_ !_R.D\;73_V5#I<'%QJ<RVRX[*3\Q_+^=9/P]@2UT37+=3E8KR5 3W
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 S$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*\X^$*.FEZD'1E/G)]X8_AKT>IQG\>16%_@Q"BBBN4Z HHHH **** "BBB@
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M /BJ7_A;6M?\^=A_WP__ ,51_9F([+[Q_P!K8;N_N/8Z*\=_X6WK7_/E8?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
B444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  R +<# 2(  A$! Q$!_\0
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MKL:&PE$87^$!#T^@K:3C"G"T5>2,H1G4JR3D[)GG^J^-_$WC'7I]%\#((K6
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MES2TM>R_S.(^$7_(*U+_ *[K_P"@UZ-7.>&=(T7PY#+;6%^LK3R!COF4DGH
M *VVO[-'*-=P*X."ID (-9XB7/5<H]2L/'DIJ,NAYE\,/^1HUG_</_H=%=MH
M/A+3] O[J]M))W>YZB1@0!G/&!11B:D:E3FCY!AZ<J=/EEYF_1116!N%%%%
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)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
